Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan for fluid management and residual kidney function in peritoneal dialysis
jRCT1031230413Recruiting
- Sponsor
- Dokkyo Medical University Saitama Medical Center
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sacubitril + valsartan in chronic kidney disease (CKD), hypertension (HTN) and heart failure (HF), sponsored by Dokkyo Medical University Saitama Medical Center. Primary endpoints: Extracellular fluid volume by impedance method, Daily water removal volume and 2 more. Started Nov 2022; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)heart failure (HF)
Beyond the preview
Go deeper on jRCT1031230413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031230413.